In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-dependent cytotoxicity.

Fiche publication

Date publication

décembre 2026

Journal

Journal of enzyme inhibition and medicinal chemistry

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GAIDDON Christian , Dr GROSS Isabelle , Dr MELLITZER Georg

Tous les auteurs :
Nannini S, Sieffert C, McGown A, Gao XY, Jarvis A, Kostakis GE, Galvacsi A, Kallay C, Moraru R, Baud MG, Mandel S, Balourdas DI, Joerger AC, Orvain C, Peschard S, Nion A, Mellitzer G, Lottiaux S, Spencer J, Gross I, Gaiddon C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42163716

Résumé

Point mutations in p53 favour tumour aggressivity, particularly in gastric cancer (GC), and offer a target for small molecule-based anticancer treatments. This study focused on the p53-Y220C mutation, which causes p53 misfolding due to thermal instability associated with the creation of a pocket that may accommodate small molecules. This mutation also creates an additional free cysteine thiol group that may react with Michael acceptors. Using an integrated and approach, four compounds (AG1, AG2, AG3, and RK349) were screened for potential reactivation of p53-Y220C in GC cells. AG3, a compound with zinc chelation and Michael acceptor properties, was found to induce p53 target gene expression via p53-dependent and -independent pathways. AG3 limited reactive oxygen species production, reducing toxicity to healthy cells. Furthermore, AG3 induced p53-dependent cytotoxicity and enhanced chemotherapy response. This study presents a novel compound with p53-Y220C reactivation potential, highlighting its promise for further development.